Manufacturing Licenses Of Four Indian Drug Makers Suspended
This article was originally published in PharmAsia News
India's Health Ministry suspended the manufacturing licenses of four major state-owned drug makers it said violated good manufacturing practices. The companies were BCG Vaccines, Central Research Institute, Haffkine BioPharmaceutical and Pasteur Institute of India. Sources said the companies would be required to make changes in their infrastructure before the suspensions are lifted. They said the suspensions could last as long as a year for the companies, which make vaccines against cholera, malaria, polio, rabies and animal diseases. (Click here for more
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.